Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma.

Journal of ovarian research - 15 Mar 2023

Feng Zheng, Shao Di, Cai Yuhang, Bi Rui, Ju Xingzhu, Chen Dongju, Song Chengcheng, Chen Xiaojun, Li Jin, An Na, Li Yunjin, Zhou Qing, Xiu Zhihui, Zhu Shida, Wu Xiaohua, Wen Hao

Abstract excerpt

BACKGROUND: Homologous Recombination Deficiency (HRD) is a predictive biomarker for ovarian cancer treated with PARP inhibitors or for breast cancer treated with first-line platinum-based chemotherapy. However, limited research is documented on platinum-based treatment prediction with HRD as a biomarker in ovarian cancer patients, especially in the Chinese population. METHODS: We investigated the association...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to East Asian People
Share to Homologous Recombination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Ovarian Neoplasms

Share to Platinum

Source

Open in PubMed Open full text

Identifiers

PMID: 36922847
DOI: 10.1186/s13048-023-01129-x
PMCID: PMC10015784

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma.PMID 36922847Read ↗

Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancerSemantic proximity Read ↗

Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma.Semantic proximity Read ↗

Molecular Subgroups of HRD Positive Ovarian Cancer and Their Prognostic Significance.Semantic proximity Read ↗

The use of homologous recombination deficiency (HRD) scores in predicting the prognosis of ovarian cancerSemantic proximity Read ↗

The Impact of Homologous Recombination Deficiency on First-line Adjuvant Chemotherapy and First-line PARPi Maintenance Therapy in Chinese Patients with Epithelial Ovarian CancerSemantic proximity Read ↗

Decoding HRD: A Genomic LOH-Based Assay Associated With Platinum Response and Survival in High-Grade Serous Ovarian CancerSemantic proximity Read ↗

Mutational profiles of ovarian cancer in Chinese patients reveal potential therapeutic targets and prognostic markersSemantic proximity Read ↗

Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination SystemSemantic proximity Read ↗

A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients.Semantic proximity Read ↗

Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancerSemantic proximity Read ↗

Relationship between homologous recombination deficiency and clinical features of breast cancer based on genomic scar score.Semantic proximity Read ↗

Predictive value of homologous recombination deficiency status for survival outcomes in primary tubo-ovarian high-grade serous carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.